Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01262690 · ClinicalTrials.gov registry record · Phase 1
A Study In Healthy Subjects Of Single Doses of PF-05230901 Injected Under The Skin
A Phase 1 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 1
- Development phase
- 44
- Enrollment target
NCT01262690 is a Phase 1 study that was terminated before completion, run by Pfizer. The registered enrollment target is 44 participants.
The verdict
NCT01262690, a Phase 1 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 44 participants
- Enrollment target
Study Summary
This study will examine whether a single dose of PF-05230901 is safe and well tolerated when given to healthy volunteers by injection under the skin. An additional objective is to measure the blood concentrations of PF-05230901. Each dose will be tested in a different group of subjects starting from the lowest dose.
Interventions
- DRUG PF-05230901
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2010-11 |
| Est. Completion | 2011-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01262690
The ClinicalTrials.gov registry entry for NCT01262690 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PF-05230901 is the first listed.
NCT01262690 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01262690 about?
NCT01262690 is a clinical study titled "A Study In Healthy Subjects Of Single Doses of PF-05230901 Injected Under The Skin". This study will examine whether a single dose of PF-05230901 is safe and well tolerated when given to healthy volunteers by injection under the skin. An additional objective is to measure the blood concentrations of PF-05230901. Each dose will be tested in a different group of subjects starting from...
What is the current status of trial NCT01262690?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 44 participants. The study started on 2010-11. Estimated completion is 2011-09.
What interventions are being tested in trial NCT01262690?
The interventions under investigation include: PF-05230901 (DRUG).
Who is sponsoring clinical trial NCT01262690?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.